CASIPSA results: CT SIJ characteristics from PsA pts similar to age- and sex-matched controls, but w/ higher prevalence of erosions, found in 18% of PsA patients. Abs 1012 #ACR22 https://t.co/jdUSUoUUbf https://t.co/2NQOhncYFc

Look at these graphs and try and tell me that sex and gender doesn't matter in RA. We have seen in study after study after study - sex and gender matters. ABST0241 @erasmusmcintl #ACR22 @RheumNow https://t.co/GQnKrAp0eB https://t.co/MxHRy2kwDN

New IgG4-RD therapeutic avenues, mechanistically driven (B cell-CTL interaction): inebilizumab: registered for NMO, ph3 now obexelimab: novel dual MOA ?safer, ph3 now rilzabrutinib: BTKi, ph2 now elotuzumab: targets SLAMF7, MM registered, NIH study John Stone #ACR22 @RheumNow https://t.co/lx4bnCutlS

Pre-RA studies: a summary by Dr. Deane #ACR22 @RheumNow https://t.co/HU8JWmYM8H

One of the nicest, smartest, and hardest working young rheumatologists you will meet, and I'm sure is destined for great things. My hat off to you @SattuiSEMD, congratulations! #ACR22 @RheumNow https://t.co/dzHXeahsHT

Is channelling bias a risk, because of treating clinicians 'protecting' pre-existing autoimmune dx pts: maybe? Certainly in practice, these pts might get less combo immunoRx; this @mcgillu data would suggest so Much more to understand across tumor streams ABST0760 #ACR22 https://t.co/z1rhAJZ9gj

What imaging modality is best in GCA? Dutch study: n=42 ?GCA got all three of USS, PET/CT, MRI Overall performance basically the same between all three. Important details in 🧵 but reasonable to say you can be happy with whatever you’ve got! ABST1617 #ACR22 #ACRBest @RheumNow https://t.co/HGt0vW9Z38

To propose early intervention in pre-clinical PsA we need to first identify pts! Eder et al. PRESTO Prediction of Psoriatic Arthritis Tool Dvlped 600+ Pso M stiff, PASI, nails, fatigue pain severity Sens 61% Spe 77% for 5% proba PsA onset w/in 5yrs Abs#1612 #ACR22 @Rheumnow https://t.co/QYOIKe3nui

Tapryal et al. Diagnostic delay of >6 months contributes to poor PROs in PsA. @RheumNow #ACR22 Abstr#1507 https://t.co/dkaNhXUAeD https://t.co/6G7X7V1aRI

Data like this make us think even in the setting of a controlled clinical trial in #gout, non-white patients much less likely to achieve target serum urate! Black pts 70% less likely to reach target compared to whites! #ACR22 @RheumNow abst#1583 https://t.co/dYet7pk2l5